\n<\/p>\n
Scientists at UCLA have made a breakthrough in cancer treatment with a new cell-based immunotherapy that targets pancreatic cancer, even after it spreads to other parts of the body. <\/p>\n
In studies conducted on mice, this innovative approach not only slowed the growth of tumors but also increased survival rates. The therapy remained effective in challenging environments where tumors typically thrive. Dr. Yanruide Li, a lead author and post-doctoral scholar at UCLA, explained that their treatment attacks the cancer from various angles, making it hard for the tumor to adapt and evade these attacks.<\/p>\n
To create this therapy, researchers transformed human stem cells into a particular type of immune cell, known as invariant natural killer T cells (NKT cells). These cells were then genetically modified with a special receptor that enables them to identify and attack pancreatic cancer cells.<\/p>\n
One of the key advantages of NKT cells is that they can be used by anyone’s body without causing severe reactions. Researchers believe that a single donor can provide enough cells for thousands of treatments, potentially making this therapy more affordable and accessible.<\/p>\n
The therapy was tested in various lab models, including those that mimicked how pancreatic cancer spreads to organs like the liver and lungs. The engineered immune cells not only penetrated the tumors effectively but also remained active over time, unlike many other immune treatments that can become less effective once inside a solid tumor.<\/p>\n
The findings were recently published in a scientific journal, highlighting the potential for this therapy to target both the primary tumor and any metastases. Dr. Lili Yang, the senior author and a professor at UCLA, noted that developing a ready-to-use therapy could change the way pancreatic cancer is treated.<\/p>\n
While this new treatment shows promise, researchers have set the price at around $5,000 per dose, which is significantly lower than many personalized therapies available today.<\/p>\n
Pancreatic cancer is notoriously hard to treat, often being diagnosed only after it has spread. The tumor’s biology can also create barriers that limit the effectiveness of traditional treatments. However, this new therapy could extend its potential to other cancer types, as it targets a protein found in several cancers, including breast and ovarian cancer.<\/p>\n
After promising results so far, the UCLA team is making plans to submit applications to the FDA to start human trials. They are hopeful that their therapy will not only be powerful and safe but also scalable for broader use.<\/p>\n
For now, all tests have been conducted in mice, and researchers are aware that human tumors present more complexities. There could also be concerns about long-term safety and side effects still to be discovered during clinical trials.<\/p>\n
Despite these challenges, the UCLA team’s work brings hope for a breakthrough in cancer treatment, with approaches that could revolutionize how we tackle this aggressive disease.<\/p>\n\n","protected":false},"excerpt":{"rendered":"
New Cancer Treatment from UCLA Researchers Shows Promise Scientists at UCLA have made a breakthrough in cancer treatment with a new cell-based immunotherapy that targets pancreatic cancer, even after it spreads to other parts of the body. In studies conducted on mice, this innovative approach not only slowed the growth of tumors but also increased<\/p>\n","protected":false},"author":1,"featured_media":21649,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rank_math_lock_modified_date":false,"footnotes":""},"categories":[32],"tags":[5378,18866,1990,19,18595,18721,18867],"class_list":{"0":"post-21648","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-cancer","9":"tag-cancer-research","10":"tag-health","11":"tag-lifestyle","12":"tag-medical-research","13":"tag-medications","14":"tag-pancreatic-cancer"},"_links":{"self":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/21648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/comments?post=21648"}],"version-history":[{"count":0,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/posts\/21648\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media\/21649"}],"wp:attachment":[{"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/media?parent=21648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/categories?post=21648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/indiabulletinusa.com\/wordpress\/wp-json\/wp\/v2\/tags?post=21648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}